Prescription for Advair (Salmeterol/Fluticasone) 50/250 mcg
For Advair (salmeterol/fluticasone) 50/250 mcg, prescribe one inhalation twice daily (morning and evening), approximately 12 hours apart. This dosing regimen provides optimal therapeutic effect while minimizing potential adverse effects 1, 2.
Prescription Details
- Medication: Advair Diskus (salmeterol/fluticasone) 50/250 mcg
- Dosage: 1 inhalation twice daily
- Timing: Morning and evening, approximately 12 hours apart
- Duration: 30-day supply with refills as appropriate
- Special Instructions: Rinse mouth with water after use to prevent oral candidiasis
Rationale for Dosing
The 50/250 mcg strength of Advair contains:
- Salmeterol 50 mcg (long-acting beta-agonist)
- Fluticasone propionate 250 mcg (inhaled corticosteroid)
This combination provides:
- Long-acting bronchodilation (salmeterol) that lasts approximately 12 hours 1
- Anti-inflammatory effects (fluticasone) to control underlying airway inflammation
Important Clinical Considerations
Proper Administration
- Patient should be instructed on proper Diskus inhaler technique
- Advair should never be used for acute symptom relief 3
- A short-acting beta-agonist should be prescribed separately for rescue use
Monitoring
- Reassess the patient in 2-4 weeks after starting therapy to evaluate:
- Symptom control
- Frequency of rescue medication use
- Proper inhaler technique
- Medication adherence
- Any side effects 3
Safety Precautions
- Advair contains a LABA (salmeterol) which should never be used alone for asthma due to increased risk of asthma-related death 3
- Instruct patient to rinse mouth after use to prevent oral candidiasis 3
- Monitor for potential steroid side effects with long-term use
Dose Adjustments
- If symptoms are well-controlled after 3 months of therapy, consider stepping down therapy 3
- If symptoms persist, consider stepping up to a higher dose formulation and reevaluate in 2 weeks 3
Common Pitfalls to Avoid
Incorrect frequency: Advair must be used twice daily, not as needed or once daily. Studies show that once-daily dosing does not maintain improvements in lung function for a full 24 hours compared to twice-daily dosing 4.
Using for acute symptoms: Advair is not for rescue use and should not be prescribed for acute symptom relief. A separate short-acting beta-agonist should be prescribed for breakthrough symptoms.
Poor inhaler technique: Ensure the patient can properly use the Diskus device, as improper technique significantly reduces medication delivery.
Abrupt discontinuation: Never discontinue Advair abruptly, especially in patients with chronic asthma. The dose should be tapered gradually under physician supervision 3.
Inadequate monitoring: Regular follow-up is essential to assess response and adjust therapy as needed.